Our reported evidence on multiple effects induced by D609 on HER2 downmodulation from the plasma membrane suggests the interest of further evaluating in appropriate model systems the added value of including a PC-PLC inhibitor as an adjunct to the current therapies targeted against HER2-overexpressing breast cancer cells. This evidence concerns the gene ERBB2 and breast carcinoma.